Attorneys from Arnall Golden Gregory examine and offer advice on FDA’s intensified scrutiny of drug advertising, advising companies to prepare for closer examination of promotional claims, supporting data, social-media content and the use of artificial intelligence.

A new report from Senate HELP chair Bill Cassidy (R-LA) targets FDA for allowing the abortion drug mifepristone’s Risk Evaluation and Mitigation Strategy to remain in place without requiring sponsors to conduct meaningful oversight of prescribing patterns.